CENTERS FOR DISEASE CONTROL

MNNR

MORBIDITY AND MORTALITY WEEKLY REPORT

February 8, 1985 / Vol. 34 / No. 5

- 65 Elimination of Rubella and Congenital Rubella Syndrome — United States
- 66 Preventing Lead Poisoning in Young Children — United States
- 73 Hepatitis B among Dental Patients Indiana
- 75 Update: Influenza Activity United States
- 76 Ansamycin LM427

Current Trends

Elimination of Rubella and Congenital Rubella Syndrome — United States

The administration of more than 123 million doses of rubella vaccine since 1969, the year of licensure, has successfully prevented epidemics of rubella and congenital rubella syndrome (CRS) from occurring in the United States (1,2). Reported cases of rubella and CRS are at all-time lows. The provisional 1984 totals for rubella cases and confirmed and compatible cases of CRS are 745 and two, respectively. Compared to prevaccine years, the number of reported rubella cases has decreased 98.7% overall, with 90% or higher declines recorded for all age groups (3-5). Similarly, the number of reported confirmed and compatible CRS cases has declined by 97.1% since 1970, the year the highest number of such cases was reported (4). Although there is believed to be underreporting of both rubella and CRS, these figures represent considerable progress.

Rubella vaccination has had a dramatic effect on the occurrence of rubella and CRS. Nonetheless, CRS cases continue to be reported at a low endemic level because the current 10%-20% susceptibility rate to rubella in the childbearing-aged population (6-8) has changed little from that noted in prevaccine years (9). The initial vaccination strategy adopted by the United States was aimed at controlling rubella in preschool-aged and young school-aged children, the known reservoirs for rubella transmission (9). The intent was to prevent exposure of susceptible pregnant women to rubella virus (10). Accordingly, the primary target group for vaccination was children of both sexes. Secondary emphasis was placed on vaccinating susceptible adolescents and young adults, especially women. While more than 95% of school enterers now provide evidence of immunization against rubella, comparable levels of rubella immunization have not been achieved in the postpubertal population. As a result, there is continuing endemic rubella activity among adolescents and young adults (3,11).

As the highly immune cohorts of young children enter the childbearing age, CRS can be expected to disappear from this country. However, since this process will take 10-30 years, potentially preventable cases of CRS will occur (2). It is estimated that each case incurs an average lifetime cost of over \$200,000 (12). Furthermore, unnecessary instances of miscarriages, stillbirths, and induced abortions resulting from congenital infection will continue to occur.

Recent focus on the continued occurrence of rubella in childbearing-aged populations has led to increased efforts to effectively vaccinate this population and thus hasten the elimination of CRS (3-5,11). The number of doses of rubella vaccine administered in the public sector to postpubertal individuals doubled between 1978 and 1981 (3). The trend of increasing vaccination of this population is continuing. This has been accomplished in part by vaccinating susceptible students attending junior and senior high schools, clients of family planning clinics, hospital personnel, college and university students, women following premarital screening, and women immediately postpartum.

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES / PUBLIC HEALTH SERVICE

Rubella and Congenital Rubella Syndrome - Continued

There still are, however, gaps in attempts to hasten CRS elimination. A number of states do not require proof of rubella immunity for postpubertal female elementary and secondary school students. The same is true of many colleges, universities, and health-profession institutions. When women are seen by internists or obstetricians/gynecologists, rubella immune status is not commonly considered. When women are screened for rubella immunity either premaritally or prenatally or in family planning clinics, only a low proportion of susceptibles so identified are subsequently vaccinated.

An initiative to hasten elimination of rubella has recently begun. As with measles elimination, efforts to eliminate CRS are aimed at (1) achieving and maintaining high immunization levels, (2) intensified surveillance of rubella and CRS, and (3) prompt outbreak control (2,11). Specific activities will focus on further increases in the delivery of rubella vaccine to women of childbearing age and enhancement of the lay and medical communities' awareness of the current rubella and CRS situation.

Vaccination of a nonschool-based population poses many logistical problems. A multi-faceted approach that involves both the public and private sectors will be needed (2,13). Furthermore, information that may help identify select groups at increased risk of not being vaccinated will have to be sought to help focus vaccination efforts. However, considering the economic impact of CRS and the other outcomes of rubella infection during pregnancy, any effort that can hasten the elimination of CRS should be undertaken.

Reported by Div of Immunization, Center for Prevention Svcs, CDC.

References

- Preblud SR, Serdula MK, Frank JA Jr, Brandling-Bennett AD, Hinman AR. Rubella vaccination in the United States: a ten-year review. Epidemiologic Reviews 1980;2:171-94.
- Orenstein WA, Bart KJ, Hinman AR, et al. The opportunity and obligation to eliminate rubella from the United States. JAMA 1984;251:1988-94.
- CDC. Rubella and congenital rubella—United States, 1980-1983. MMWR 1983;32:505-10.
- CDC. Rubella and congenital rubella United States, 1983. MMWR 1984;33:237-42, 247.
- CDC. Rubella and congenital rubella syndrome—United States, 1983-1984. MMWR 1984;33: 528-31.
- Preblud SR, Gross F, Halsey NA, Hinman AR, Herrmann KL, Koplan JP. Assessment of susceptibility to measles and rubella. JAMA 1982;247:1134-7.
- Dales LG, Chin J. Public health implications of rubella antibody levels in California. Am J Public Health 1982;72:167-72.
- Blouse LE, Lathrop GD, Dupuy HJ, Ball RJ. Rubella screening and vaccination program for U.S. Air Force trainees: an analysis of findings. Am J Public Health 1982;72:280-3.
- 9. Witte JJ, Karchmer AW, Caes G, et al. Epidemiology of rubella. Am J Dis Child 1969;118:107-11.
- Hinman AR, Bart KJ, Orenstein WA, Preblud SR. Rational strategy for rubella vaccination. Lancet 1983;1:39-40.
- 11. ACIP. Rubella prevention. MMWR 1984;33:301-10, 315-8.
- Koplan JP, White CC. An update on the benefits and costs of measles and rubella immunization. In: Proceedings of the symposium "Conquest of agents that endanger the brain." Baltimore, Maryland, October 28-29, 1982 (in press).
- Doster SW, Stetler HC, Orenstein WA, Bart KJ, Hinman AR. Measles and rubella: our remaining responsibilities [editorial]. Am J Public Health 1983;73:490-2.

Preventing Lead Poisoning in Young Children — United States

CDC has issued a new statement on preventing lead poisoning in young children (1). This statement replaces the 1978 statement (2), which defined levels for elevated blood lead, undue lead absorption, lead toxicity, and lead poisoning. The 1985 statement is intended to serve as a guideline for lead-poisoning prevention programs in the United States.

Since 1978, investigators have reported adverse effects from low-level lead exposure on children's behavior and intelligence (3), hemoglobin formation in red blood cells (4), and

Lead Poisoning - Continued

metabolism of vitamin D (5). These studies demonstrate that little or no margin of safety is associated with a level of 30 micrograms of lead per deciliter ($\mu g/dl$) of whole blood—the lowest level defined as elevated in CDC's 1978 statement.

To be successful, a screening program designed to prevent childhood lead poisoning requires, not only an acceptable and cost-effective screening procedure, but also medical follow-up and means of preventing the child from future exposure to lead (6). The erythrocyte protoporphyrin (EP) test is recommended as the screening test for lead toxicity because it can be easily performed on a drop of blood obtained from a finger prick and placed in a portable fluorometer. Since EP levels increase in both lead poisoning and iron deficiency, follow-up testing for elevated blood lead and/or iron deficiency must be done.

Some major changes in the 1985 statement compared with the 1978 statement are:

- An elevated blood lead level, which reflects excessive absorption of lead, is defined as a concentration of lead in whole blood of 25 μg/dl or greater (formerly 30 μg/dl or greater).
- Lead toxicity is defined as an elevated blood lead level with an EP level in whole blood of 35 μg/dl or greater (formerly 50 μg/dl or greater).
- Lead is most harmful to children between the ages of 9 months and 6 years. Ideally, all children should be screened. As more children are screened for iron deficiency by EP testing, simultaneous lead screening of these same groups becomes feasible.
- 4. For EP levels greater than 35 μg/dl, EP values obtained with hematofluorometers are generally lower than EP values obtained by the extraction method. Therefore, separate cutoff levels are used for classifying the urgency of medical follow-up.
- Greater reliance is placed on the calcium disodium EDTA mobilization ("Provocative Chelation") test in determining whether a full course of chelation therapy is indicated for children with blood lead levels in the 25-55 μg/dl range.

The revised lead statement, Preventing Lead Poisoning In Young Children: A Statement by the Centers for Disease Control: January 1985, will be available on request after March 1, 1985, from: Publication Activities, Center for Environmental Health, Centers for Disease Control, Atlanta, Georgia 30333; (404) 452-4102.

Reported by Special Studies Br, Chronic Diseases Div, Center for Environmental Health, CDC.

Editorial Note: The second National Health and Nutrition Examination Survey (NHANES II, 1976-1980) found that children from all geographic and socioeconomic groups are at risk of lead poisoning (7). An estimated 3.9% (or nearly one of 25) of the children in the United States under 5 years of age had blood lead levels of 30 μ g/dl or greater—levels possibly causing adverse physiologic and neurobehavioral effects. Between 1976 and 1980, the overall mean blood lead levels dropped from 14.6 μ g/dl to 9.2 μ g/dl, and this corresponded with a decline in the sales of leaded gasoline during this period (8).

Lead-based paint continues to be the major source of high-dose lead exposure and asymptomatic lead poisoning for children in the United States. Since 1977, paint produced for household use must, by regulation, contain no more than 0.06% (600 parts per million [ppm]) lead by dry weight, but some paints manufactured in the 1940s for indoor use contained more than 50% (500,000 ppm) lead. An estimated 27,000,000 households in this country remain contaminated by lead paint (9).

Typically, symptomatic lead poisoning occurs among children under 6 years old living in deteriorated, pre-World War II housing. Repeated ingestion of nonfood substances has been shown to be associated with lead poisoning in young children (10), but it is not a prerequisite for lead poisoning (11), since children's normal mouthing behavior alone is sufficient to cause those living in contaminated homes to have high lead exposure. Lead poisoning has been reported in children whose parents moved to a city as "urban homesteaders"; the children were exposed to chips, dust, or fumes from lead-based paint when the old houses were remodeled or renovated (10).

Other potential sources of lead exposure include the use of imported lead-glazed pottery for cooking (12) or storing food and hobbies and activities involving lead, such as working with stained glass or casting lead objects.

The highest priority for screening should be given to 12- to 36-month-old children who live in or frequently visit older, dilapidated housing, who live near lead smelters or other industrial sources of lead, or whose parents work with materials containing lead.

Screening all children for lead toxicity—including those not suspected of having been exposed to lead—is feasible, since the EP test can also be used as the screening for iron deficiency. Recently, in a nutritional assistance program, the EP test was used to screen children for iron deficiency (13), and some Hmong refugee children were found to have lead toxicity. The source was traced to a Hmong folk remedy used for treating infants and children with fevers.

References

- CDC. Preventing lead poisoning in young children: a statement by the Centers for Disease Control: January 1985. Atlanta, Georgia: Department of Health and Human Services, 1985.
- CDC. Preventing lead poisoning in young children: a statement by the Center for Disease Control: April 1978. Atlanta, Georgia: Department of Health, Education, and Welfare, 1978.
- Needleman HL, Gunnoe C, Leviton A, et al. Deficits in psychologic and classroom performance of children with elevated dentine lead levels. N Engl J Med 1979;300:689-95.

(Continued on page 73)

TABLE I. Summary-cases of specified notifiable diseases, United States

154 88 N 509 348 N 109 349 3				5th Week End	ing	Cumulative, 5th Week Ending				
1		Disease						Median 1980-1984		
Septic mannights 56 88 38 311 484 433 434 435	Acquired Imr	munodeficiency Syndrome (AIDS)								
Businger 18			55	88	88	311	464	433		
Businger 18	Encephalitis	Primary (arthropod-borne								
Post-infectious 16,575 15,247 19,189 74,295 81,011 92,424 19,189 74,295 81,011 92,424 19,189 74,295 81,011 92,424 19,189 74,295 81,011 92,424 19,189 74,295 81,011 92,424 19,189 1			18	21	13					
Military 1933 409 622 1,414 2,049 2,572			1		9					
April	Gonorrhea	Civilian	16,575							
Type B 552 516 375 1.978 2.121 1.666 Non A, Non B 191 71 183 353 363 752 185 185 185 185 185 185 185 185 185 185		Military	393		622					
Non A, Non B	Hepatitis	Type A	474	402						
Non A, Non B	- Top a state		552	516	375	1.978	2,121	1,666		
Unspecified 91 71 183 353 363 752 #growthous		Non A. Non B	74	71	N	316	302			
12 5 N 48 31 N			91	71	183	353		752		
1 1 4 10 16 14	Legionellous			5	N	48	31	N		
Malara 13 16 16 49 61 61 61 61 61 61 61 6			1	1	4	10	16	14		
Measies Total	Malana		13	16	16	49	61	61		
Indigenatus 1 52 N 3 87 N					40	23	143	143		
Imported 10 49 N 20 56 N Meningococal infections Total 65 64 62 224 257 279 259 Mintary 1 1 1 1 1 1 1 1			1				87	N		
Meningococcal infections Total 65 64 62 224 257 277			10			20	56	N		
Crivilian 65 64 62 224 257 289 Military				64	62	224	257	277		
Maintary 46 61 75 199 301 379	real margarate						257	269		
Managas 46 61 75 199 301 379			00	-				1		
17 15 29 84 117 95	Marmore	, and a	46			199	301	379		
Rubertal German meastest 2 7 35 16 35 137 35 35 35 35 37 35 35							117	95		
Syphids (Primary & Secondary)		www.en.ene.asslas1		7				137		
Toxic Shock syndrome				607						
Toxic Shock syndrome	cakbaums is an		2		7			42		
Tubertuknis 282 388 442 1,380 1,559 1,912 Tubertuknis 5	Toxic Shock		8		M			N		
Fullaramia 5 - 2 13 3 8 Fughorio fever (rightus fever tick-borne (RMSF) - 1 1 2 6 6 6								1.912		
Typhoid fever 6 4 7 13 26 32 Typhus fever, tick-borne (RMSF) - 1 1 2 6 6				200	2			8		
Typhus fever, tick-borne (RMSF) - 1 1 2 6		er .		A	7					
				1	1			6		
0, 04 55 257 551 44.6			61	84	93					
	macres, and	1481	21	0.4	33	231	331	46		

TABLE II. Notifiable diseases of low frequency, United States

	Cum 1985		Cum 1985
Anthrax		Plague	
Botulism: Foodborne		Poliomyelitis: Total	
Infant	3	Paralytic	
Other		Psittacosis (W. Va. 6, Ariz. 1, Calif. 2)	14
Brucellosis (Upstate N.Y. 2, Mich. 1, Calif. 1)	5	Rabies, human	
Cholera		Tetanus (W. Va. 1)	3
Congenital rubella syndrome		Trichinosis	4
Diphtheria		Typhus fever, flea-borne (endemic, murine)	
Laptospirosis	5		

Five of the 11 reported cases for this week were imported from a foreign country or can be directly traceable to a known internationally imported case within two generations.

TABLE III. Cases of specified notifiable diseases, United States, weeks ending February 2, 1985 and February 4, 1984 (5th Week)

	AIDS	Aseptic Menin-	Encep	shalitis	Gono	rrhea	H	epatitis (V	iral), by ty	pe	Legionel-	
Reporting Area		gitis	Primary	Post-in- fectious	(Civ	lian)	A	В	NA,NB	Unspeci- fied	losis	Leprosy
	Cum. 1985	1985	Cum. 1985	Cum. 1985	Cum 1985	Cum 1984	1985	1985	1985	1985	1985	Cum. 1985
UNITED STATES	509	55	60	5	74,295	81,011	474	552	74	91	12	10
NEW ENGLAND	17	9	2	e	2,449	2,728	9	28	4	21	1	-
Maine N.H.	1	i	í		101	106	*	2		*		-
Vt.				-	47 26	61 33		3	1.	*		*
Mass.	11		1		843	985	5	16	3	19		
R.I. Conn	1	*	*		166	134	2	3		:	1	-
Com	4		*	*	1,246	1,409	2	6	8	2		-
MID ATLANTIC	218	5	2		9,864	9,583	29	68	6	6	1	1
Upstate N Y N Y City	41	5	2		958	1,417	15	37	4	4	*	
NJ	130				4,278 1,352	4,116 1,374	3 8	9	*	1	-	1
Pa.	16			*	3,276	2,676	3	17	2		1	-
EN CENTRAL	36	12	20									
Ohio	9	3	8	2	10,544 2,798	12,130 2,662	42	51	5	2	5 4	*
Ind.	2		4		959	1,607	3	8	1	1		
00	15	2	*	-	3,601	3.462	3	3		1	-	
Mich Wis	6	7	7	-	3,019	3.245	28	30	4	*	1	
	4		1	1	167	1,154		•		~		
WN CENTRAL	8	2	3		4,300	3,603	13	21	2	1	1	-
Minn	1		2	~	639	555	3	6		1		
lowa Mo	1 4		3	~	1,952	463 1,550	1	2	1		i	
N Dak	-				24	39	-	12	1	-		
S Dak		2		*	91	122	9	1		-		
Nebr Kans		~	~	-	400	270			*	*	*	*
Karis	2	*		*	745	604	-	*	*	1	~	
S ATLANTIC	57	9	8		15,614	20,247	17	77	8	4	1	
Del	1		1		355	335	2	1	*			
Md D C	10	1	2		2,089 1,257	2.867 1.438		6	3	2	-	•
Va	6	3		-	1,657	2,082	1	14	1			2
W Va	*			-	255	216	-	2			*	
N C S C	6	1	5	-	3,008	3.091	1	7	1		*	
Ga	7				2,222	1,879 3.968	1	12	1	1	1	*
Fla	19	4			4,771	4,371	12	22	2	i		-
ES CENTRAL	4	5	2	2	6,310	6,561	14	39	2	1		
Ky	1	3			714	866	13	17	1	1		-
Tenn			1		2,577	2.687		14				
Ala	2	1	1	2	2.035	2,111		6	1	*	*	-
Miss	1	1			984	897	1	2				
W S CENTRAL	36	5	3		11,757	11,096	55	20	5	26		
Ark	-			-	1,112	1,020	1	*	*	-		
Okla	1	2	3		2,390 1,166	1,287	14	5	3	ā	~	-
Tex	35	3			7,089	6,041	35	13	1	22	-	
MOUNTAIN Mont	12	4	3	-	2,464	2,384	55	36	3	7		
Idaho				-	82	104	3	1	1			-
Wyo				-	45	63		1				
Colo	4	*	2	-	630	604	11	5		1	-	
N Mex Arız	2 4		*	*	316 806	293 641	14	13	1	2		-
Utah	-	4	1	-	106	135	5	11		4		-
Nev	2	~			399	427	5	5	*	-		
PACIFIC	121	12	17	1	10,993	12,679	240	212	39	23	3	9
Wash	121	12	1		620	788	12	10	2	23	3	9
Greg	4				662	643	19	15	2			1
Calif	116	11	16	1	9,262	10,791	209	186	35	23	3	7
Alaska Hawan	-	1			292 157	275 182		1	-	-		i
					101							,
Guam P.R		U	-	*	410	31	U	U	U	U	U	
VI	8	2	1		419 39	301 49	14	8	1		-	
Pac. Trust Terr		U			20	40	Ü	U	U	U	U	

TABLE III. (Cont'd.) Cases of specified notifiable diseases, United States, weeks ending February 2, 1985 and February 4, 1984 (5th Week)

Reporting Area	Maloria	Measles (Rubeola)					Menin- gococcal	Mur	mps		Portussis		Rubella			
	Cum.	-	Cum		Cum:	Total Cum.	Infections Cum.		Cum	-	Cum	Cum	1985	Cum	Cum	
	1985	1985	1985	1985	1985	1984	1985	1985	1985	1985	1985	1984	1985	1985	1984	
UNITED STATES	49	1	3	10	20	143	224	46	199	17	84	117	2	16	35	
NEW ENGLAND	9						15	9	7	-	1	2		2	7	
Maine N.H.							1		1	-		1		2		
Vt.				-	-	*	2	-			1	*			*	
Mass.	1	*		*	*	*	3	1	5	-	-	1		1	-	
R.I. Conn.		-	2				3		1		*	-	-			
MID ATLANTIC	7			1	1		24	4	31	2	16	5	1	5		
Upstate N.Y.	2			11	1	*	8	4	26	1	4	5	1	1		
N.Y. City	2		*	*		*	1	*	3		4	*	*	3	-	
N.J. Pu	3		*	~	-	*	8 7		2	1	8				-	
		-								-					4	
E.N. CENTRAL	4	*	1	*	-	103	48	14	59 31	2	19	15	*		-	
Ohio Ind.	1			-			5	3	6	2	10	-	-			
MI.		*	-		*	11	3		8	*	-	5	*	*	3	
Mich. Wis.	3	*	1			92	16	5	13		1	3			1	
				-							-	41		1	2	
W.N. CENTRAL.	1		*	*			12	2	6	4	5	2			4	
fowa					-		2	*	1			3				
Mo.	1						6	2	3	2	2	1	*		i	
N. Dak.	*		*		*		í	*		2	2		-			
S. Dak. Nebr.			-		-					*		2				
Kans.		*		*		*		-	2		-	33		1	1	
S. ATLANTIC	7	1	1	1	1		34	4	17	6	11	14	*	1	2	
Clei.	- :	*	-	*		*	1			i	i	í		-		
RAd. DLC.	1		-	11	1		4									
Va.	1				*		4	1	5			4	*	*	*	
W. Va.	1	*	*	*				2	6	2	4	2				
N.C.	1	*							1					1		
Ge							3		2	1	1	3			1	
Fla.	2	1	1				7	1	3	2	5	3	-		,	
E.S. CENTRAL	2					2	13	*	1		2	2		1		
Ky. Tenn.			*	*	-	2	6	-	1	*	1	1				
Ala	2				-		4			-	1			*	-	
Miss.			~		-		. 1	-		-	*				*	
W.S. CENTRAL	1					7	13	4	16		4	12		1	4	
Ark.			*					*	1	*	2	7		1	1	
Ckia.							1	N	N		2	2			-	
Tex	1					7	11	4	15	*		3	-		3	
MOUNTAIN				5	8	17	1 15	4	25	1	3	12			3	
Mont.				5 9	8		. 2		1	*	~	1		*		
Idaho			*					*	2		*	1			1	
Wyo. Cole					-		. 4	1	4	1	1	9				
N. Mex.				*			. 3	N	N	-	1	1	*	~	-	
Ariz			-			1	3 2	2	16	-	1				2	
Utah Nev				-			- 1	1	2						-	
	26		1	3	10	1	4 50	13	37	2	23	14	1	5	19	
PACIFIC Wash	20		1	3	10		2 6	1	2		1	6				
Oreg							- 3	N	N		4	4	1	5	19	
Cast	20		1	3 1	9	10	0 41	11	30		15	4		9	19	
Alaska Hawan					1		2 -	1	4	2	2					
				U			9 .	U		U			u	-	1	
Guam P.R.		- U	15				. 8	2	11		1		. 2	2	1	
VI		- 2	2		-				1	-						
Pac. Trust Terr.		- U		U				U		U			· U	-		

^{*}For measles only, imported cases includes both out-of-state and international importations.

TABLE III. (Cont'd.) Cases of specified notifiable diseases, United States, weeks ending February 2, 1985 and February 4, 1984 (5th Week)

Reporting Area UNITED STATES	Syphilis (Primary &	(Civilian) Secondary)	Toxic- shock Syndrame	Tuber	culosis	Tuta- remia	Typhoid Fever	Typhus Fever (Tick-borne) (RMSF)	Raties
	Cum 1985	Cum. 1984	1985	Cum 1985	Cum 1984	Cum 1985	Cum. 1985	Cum 1985	Cum 1985
UNITED STATES	2,214	2,648	8	1.380	1,559	13	13	2	237
NEW ENGLAND	54	71		48	46	-	1		
Maine	2	1	*	2	4			-	
N.H. Vt.				-	3			-	
Mass	. 26		*					*	
RI	. 20	46		32	16	-		-	
Conn	25	21	2	6 8	14	2	i	-	2
MID ATLANTIC	316	330		345					
Upstate N Y	15	31		345	298		1	*	57
N Y City	200	187		170	131		1	*	9
LN	62	62		56	71			*	
Pa	39	50	×	85	55	-			48
EN CENTRAL	118	148	3	162	195			1	
Ohio	10	29	1	30	49			1	4
ind	8	21		19	21				
100	77	72		75	79				1
Mich	18	17	2	29	36				
Wis	5	9	-	9	10	*		*	3
WN CENTRAL	19	49	1	28	41	4	2		29
Minn	6	12		4	3	-	2	-	29
lowa Mn		4	1	12	8	*	-	*	17
Mo N Dak	8	26		5	19	3	*	-	4
S Dak	1		-	-	1	*		*	5
Vetir	1	3		2 2	1	-	*	~	
Kans	3	4		3	5	1			2
SATLANTIC	539	020							
Del	3	828	1	275	362	3	3	1	17
Md	47	44		32	53	-	1		
DC	25	23		18	8			-	-
Va	32	44		9	30		1		5
W Va		5		10	12				-
N C S C	68	73		24	62	3	*	1	
Ga	75	86 146		36	51		*		2
Fla	289	407	1	113	103		1	-	10
C CENTRAL	245						,		
S CENTRAL	215	169		102	142	1		-	14
lenn .	36	45	*	15 31	30 51		*		2
Ala	88	60	-	53	58	1			1
Wess	82	57	-	3	3				11
WS CENTRAL	477	586	1	102	99				
Ark	32	20		6	1	1	-		46
i di	109	134		41	22				6
Okla	22	13	1	16	12	1			4
lex .	314	419		39	64	*			33
MOUNTAIN	92	59		21	29	3			35
Mont	-	141		2	1		-		11
daho	1	2	*	-	1	-	-		
Myo	2	1		-	-		*	~	2
Colo I Mex	19	7 8			-		-	*	
Ariz	58	20		14	16	1	*	~	1
Itah	1	3			10	2			21
Sev	4	18	-	3	i	-			-
ACIFIC	384	408	2	297	347				
Vash	-	17	1	5	17	1	6	*	35
reg	15	13		9	13	1		-	-
aid	362	366	1	275	282		6	-	35
Maska			*	*	8		-	-	35
lawan	7	12	~	8	27		-	*	
iuam			U						
n	105	91		16	22		1	-	1
ac Trust Terr		1	*	~	*	*			
	-	m	U		-	-	-	-	

TABLE IV. Death in 121 U.S. cities," week ending February 2, 1985 (5th Week)

		All Caus	es, By A	ge (Year	a) l		Pair* Total Ra		All Causes, By Age (Yeers)						
Reporting Area	All Ages	≥65	45-64	25-44	1-24	<1		Reporting Area	All Ages	>65	45-64	25-44	1-24	<1	P&I* Tota
NEW ENGLAND	824	618	131	40	15	19	78		1,520	973	364	95	34	53	62
loston, Mass.	231	166	43	12	4	6	29	Attanta, Ga.	178	105	49	16	6	2	4
ridgeport, Conn.	67	53	6	6	1	1	4	Bultimore, Md.	349	206	95	25	10	13	- 6
ambridge, Mass	26	23	1	2		*	4	Charlotte, N.C.	81	52	18	4	2	5	- 4
all River, Mass.	25	21	4		*	*	1	Jacksonville, Fla.	129	86	35	6	2		
tartford, Conn.	73	51	13	2	2	4	3	Miami, Fla.	147	85	49	8	1	4	-
owell, Mass.	24	22	1	*	*	1	2	Norfolk, Va.	57	32	11	4	1	9	-
ynn, Mass.	18	14	4	150	*	*	2	Richmond, Va.	92	54	31	3	2	2	-
iew Bedford, Mass		22	1	1	1		1	Savannah, Ga.	58	35	15	6	3	3	2
Vew Haven, Conn.	86	57	19	6	2	2	2	St. Petersburg, Fla.	163	135	16	9	3	5	-
rovidence, R.I.	86	69	11	2	3	1	11	Tampa, Fla.		104	1	5	3	6	- 1
iomerville, Mass	15	11	2	1	1		2	Washington, D.C. §	119	42	16	3	2	4	- 1
gringfield, Mass	57	41	13	1	*	2	4	Wilmington, Del.	67	92	10	3	46	-	
Waterbury, Conn.	24	19	3	2	-		3	E.S. CENTRAL	854	546	207	46	30	24	64
Norcester, Mass.	67	49	10	5	1	2	10	Birmingham, Ala.	122	78	31	6	3	4	-
			700			22			55	40	12	2	1	-	
	3,349	2,287	703	213	68	77	211	Chattanooga, Tenn. Knosville, Tenn.	78	48	21	5	4	-	
Albany, N.Y.	64	40	15	3	4	2	1	Louisville, Ky.	134	85	27	8	5	9	1
Allentown, Pa.	14	13	1	10	3	4	22	Memphis, Tenn.	191	125	45	10	7	4	9
Buffalo, N.Y.	232	163	42	19				Mobile, Als.	64	45	10	4	2	2	
Camden, N.J.	59	36	17	2	4	*	2 2	Montgomery, Ala.	77	48	17	7	4	1	
Elizabeth, N.J.	25	19	3	3		1	9	Nashville, Tenn.	133	77	44	4	4	4	1
Erie, Pa.†	56	47 37	15	3	*	2	2	reagritude, result.	133			~	-	-	
Jersey City, N.J.	57				40	33	119	W.S. CENTRAL	1.305	806	284	97	46	71	8
N.Y. City, N.Y.	1.795	1,219	372	131			3	Austin, Tex.	51	28	10	9	2	2	-
Newark, N.J.	125	61	36		5	13		Baton Rouge, La	46	34	4	6	1	1	
Paterson, N.J.	45	29	10	3		2	23	Corpus Christi, Tex	65	42	14	5	2	2	
Philadelphia, Pa.†	318	205	76	21	7	9		Dallas, Tex.	217	126	50	18	6	17	1
Pittsburgh, Pa.†	109	75	23	7	*	4	5	El Paso, Tex	70	38	23	5	1	3	1
Reading, Pa.	30	25	4	1	-	*	2	Fort Worth, Tex.	100	53	23	8	6	9	1
Rochester, N.Y.	143	117	21	2	3		12	Houston, Tex	170	102	45	6	11	6	
Schenectady, N.Y.	32	24	6	1	*	1				32	10	5	3	4	
Scranton, Pa t	20	15	5				1	Little Rock, Ark	54	88	33		1	5	
Syracuse, N.Y.	106	73	25	3	1	4	2	New Orleans, La.	137	142	42		9	14	2
Trenton, N.J.	46	33	9	2		2	1	San Antonio, Tex	224	51	13		1	3	4
Utica, N.Y.	24	18	5	1	*	*	2	Shreveport, La	73				3	5	
Yonkers, N.Y.	49	38	10	1		*	1	Tulsa, Okla.	98	70	17				
EN CENTRAL	2,632	1.843	477	129	73	109	132	MOUNTAIN	780	509 66	170		29	18	4
Akron, Ohio	70	47	16		4	3	4	Albuquerque, N Mer			14			1	
Canton, Ohio	42	33	7	. 1	1		6	Colo Springs, Colo	119	25 84	25		3	3	1
Chicago, III §	568	465	13	29	18	42	17	Denver, Colo		72	26		- 6	1	1
Cincinnati, Ohio	208	140	46	9	6	7	25	Las Vegas, Nev	115		20			3	
Dieveland, Ohio	201	125	54	7	5	10		Ogden, Utah	26	17			9	5	
Columbus, Ohio	131	92	26	6	3	4	7	Phoenix, Anz	179	111	40		2	9	
Dayton, Ohio	144	102	35	4	2	1	3	Pueblo, Colo	32	23	5		1	3	
Detroit, Mich.	312	190	69	29	11	13		Salt Lake City, Utah		27	13			2	
Evansville, Ind.	55	36	17	1	-	1	3	Tucson, Ariz	111	84	20	3	2	2	
Fort Wayne, Ind.	66	47	8	5	1	5		BACIDO	2.421	1 222	442	146	49	55	2
Gary, Ind.	18	7	5	1	5			PACIFIC	2,431	1,727			49	22	2
Grand Rapids, Mic	h 62	44	15	3	-		9	flerkeley, Cald	25	17	13		1	3	
Indianapolis, ind.	209	132	52	11	5	9		Fresmo, Calif	86		13		1	3	
Medison, Wis.	37	22	11	1	1	2		Glendale, Calif.	28	16	14		1		
Milwaukee, Wis.	160	110	35	6	2	7		Honduki, Hawaii	75	55			4	6	
Peons, III	53	35	9	5	2	2		Long Beach, Calif	127	82	25				
Rockford, III.	60	46	8	4	1	1		Los Angeles, Calif.	639	453	120		13	13	
South Bend, Ind.	46	37	7	1	1	-		Oakland, Calif.	96	67	15		4		
Toledo, Ohio	122	79	32	4	5	2	7	Pasadena, Calif.	40	111	21	3 2	3	2	
Youngstown, Ohi	0 68	54	12	2	-		. 2	Portland, Oreg.	150				3		
				-				Sacramento, Calif	159	116	21			7	
W N. CENTRAL	845	588	175	38	18	36		San Diego, Calif	181	114	31		6		
Day Moines, lows	69	52	12	2	7	2		San Francisco, Cali	1 254	176	41		4	9	
Duluth, Minn.	24	17	5	1	*	1		San Jose, Calif.	235	173	31		5	3	
Kansas City, Kans		21	9	1	1		- 1	Seattle, Wash	203	158	21		4	2	
Kansas City, Mo.	117	80	28		1	1			39	27		8 1	2	1	
Lincoln, Nebr	29		3	1	2	-	- 1	Tacoma, Wash	94	64	2	4 2	1	3	E.
Michappin Min	n 90	62	19	2	3	- 4			1	t t					
Omiatra, Nebr	95	64	20	5	2	- 1			14,540	9.897	2.95	3 856	362	452	9
St Louis, Mo.	210	154	35	11	3	1	1 10								
St. Paul, Minn.	63		15		-		. 2								
Wichita, Kans.	116		29		5	- 4	5 11								

^{*} Mortality data in this table are voluntarily reported from 121 crities in the United States, most of which have populations of 100,000 or more. A death is reported by the place of its occurrence and by the week that the death cartificate was filled. Fetal deaths are not

included
"Pneumonia and influenza

Final results and transersal.

1 Because of Changes in reporting methods in these 4 Pennsylvania cities, these numbers are partial counts for the current week. Complete counts will be available in 4 to 6 weeks.

17 Total includes unknown ages.

Data not available. Figures are estimates based on average of past 4 weeks.

Lead Poisoning - Continued

- Piomelli S, Seaman C, Zullow D, Curran A, Davidow B. Threshold for lead damage to heme synthesis in urban children. Proc Natl Acad Sci USA 1982;79:3335-9.
- Rosen JF, Chesney RW, Hamstra A, DeLuca HF, Mahaffey KR. Reduction in 1,25-dihydroxyvitamin D in children with increased lead absorption. N Engl J Med 1980;302:1128-31.
- Piomelli S, Rosen JF, Chisolm JJ Jr, Graef JW. Management of childhood lead poisoning. J Padiatr 1984;105:523-32.
- Mahaffey KR, Annest JL, Roberts J, Murphy RS. National estimates of blood lead levels: United States 1976-1980: association with selected demographic and socioeconomic factors. N Engl J Med 1982;307:573-9.
- Annest JL, Pirkle JL, Makuc D, Neese JW, Bayse DD, Kovar MG. Chronological trend in blood lead levels between 1976 and 1980. N Engl J Med 1983;308:1373-7.
- 9. Lin-Fu JS. Children and lead: new findings and concerns [Editorial]. N Engl J Med 1982;307:615-7.
- Chisolm JJ Jr, O'Hara DM, eds. Lead absorption in children: management, clinical, and environmental aspects. Baltimore, Maryland: Urban & Schwarzenberg, 1982.
- Sayre JW, Charney E, Vostal J, Pless IB. House and hand dust as a potential source of childhood lead exposure. Am J Dis Child 1974;127:167-70.
- 12. Bird TD, Wallace DM, Labbe RF. The porthyria, plumbism, pottery puzzle. JAMA 1982;247:813-4.
- CDC. Folk remedy-associated lead poisoning in Hmong children—Minnesota. MMWR 1983;32: 555-6.

Epidemiologic Notes and Reports

Hepatitis B among Dental Patients - Indiana

Between April 1, and December 30, 1984, nine cases of clinical hepatitis B (HB) occurred in a rural Indiana county (population 35,000); this was nine times the normal yearly HB incidence for the past decade. Two of the cases resulted in fatal fulminant hepatitis; an additional case was complicated by polyarteritis nodosa, mononeuritis multiplex, and paralysis. All cases except one had been treated by a dentist in the county.

In mid-September, the dentist, who had practiced general family dentistry in the county for 20 years and saw between 100 and 150 patients per week, noted that all three of the cases to date had been his patients. Because of his possible involvement, he was tested for hepatitis B surface antigen (HBsAg) and found to be positive. He then voluntarily suspended his practice and notified health authorities. Initial investigation by the Indiana State Board of Health and CDC revealed that seven patients who had developed clinical HB between April 1 and October 1 were among the dentist's patients. All were positive for HBsAg, subtype ad, and all of six available sera were positive for the IgM fraction of hepatitis B core antibody (anti-HBc IgM), indicating probable recent infection. Although the dentist had no known history of HB infection, his serum was positive for HBsAg, subtype ad, and hepatitis e antigen (HBeAg) but negative for anti-HBc IgM.

The dentist did not routinely wear gloves when treating patients but denied lacerations or dermatitis on the hands. He gave no history of hepatitis and had no knowledge of HB carriers in his practice. Other than practicing dentistry, he denied all risk factors for HB. He was not a blood donor and had never been tested serologically for hepatitis. On April 25, and May 30, 1984, he had received his first two doses of HB vaccine.

Further investigation of the outbreak by CDC in late October concentrated on case-finding and interviews of the dentist, his assistants, and the known HB patients and their families. Appropriate blood specimens were also taken. A comparison of the dentist's 1984 patient list with reported HB cases in Indiana uncovered no new cases. However, a review of county resi-

Hepatitis B - Continued

dents rejected for blood donation because of HBsAg-positivity found one patient, who, asymptomatic at the time, had been treated by the dentist several times between May and July and was rejected for blood donation in August. Since she had donated blood in March, her HB infection was considered outbreak-related. Clinical disease, however, did not develop until November 13, nearly 3 months after she became antigen-positive.

The spouse of one HB patient was found to be HBsAg positive, serotype ad, HBeAg positive, and anti-HBc IgM negative. He had not been treated by the dentist within the last 2 years but had other risk factors for HB. No other patient's family member had positive HB markers. The patients had no histories of risk factors for HB except traumatic dental work (procedures that produced bleeding) by the dentist 3-5 months before onset of symptoms. None of the HB patients were taking hepatotoxic drugs. Antibody and antigen tests for delta virus were negative on the dentist and all seven of the HB patients tested.

In mid-December, a large seroprevalence study was carried out on the dentist's patients in an attempt to determine the degree of subclinical transmission; results of this study are pending. The dentist has not resumed his practice.

Reported by RH Hamm, MD, RB Peare, MD, WL Painter, KC Allman, M Hamilton, K Cutting, CL Barrett, MD, State Epidemiologist, Indiana State Board of Health; Hepatitis Br, Div of Viral Diseases, Center for Infectious Diseases

Editorial Note: HB is a significant health risk for dental professionals (1,2) but is only rarely associated with transmission from dentist to patient. Seven HB outbreaks traced to dentists or oral surgeons have been reported. In each instance, the dental professional was a chronic carrier of HB virus and was HBeAg positive, indicating high titers of HB virus in blood. None used gloves when treating patients. Transmission of HB virus was thought to occur by transfer of infective serum from the dentist's hands into the patient's mouth through small abrasions, lacerations, or dermatitis. When subclinical transmission was studied, the overall rate of infection ranged from 1.5 infections per 100 patients screened to 11.1/100. The risk of transmission correlated with the amount of trauma involved in the dental procedure. For those dentists who remained carriers and returned to work, wearing gloves was usually successful in preventing further transmission (3).

The present outbreak illustrates again that HBsAg-positive dentists can unknowingly transmit infection to patients. Available epidemiologic and serologic data suggest that the Indiana dentist was infected before January 1984, too early to be affected by HB vaccine started in April, and that he probably obtained his infection while treating an HB-carrier patient. The dentist and the HB patients had matching antigenic subtypes. However, since ad subtype is extremely common in the United States, this does not prove that the dentist was the source of the outbreak as convincingly as the time/place clustering in his practice and the lack of other risk factors among the HB patients.

The 22% case-fatality rate in this outbreak is much higher than the usual rate of 1% of hospitalized HB patients. Furthermore, one patient suffered severe polyarteritis nodosa, a complication seen in no more than 1 of 500 cases. Neither coinfection with delta virus nor the use of hepatotoxic drugs explain the unusual amount of severe disease in this outbreak. CDC is continuing to investigate the possibility that a non-B hepatitis virus could be a cofactor in the outbreak.

This is the first reported outbreak of HB traceable to a dentist that has involved deaths. It illustrates an uncommon but serious consequence of HB infection in the dental profession. Outbreaks of this type should reinforce efforts to deliver HB vaccine to dental professionals early in their careers.

References

 Mosley JW, Edwards VM, Casey G, Redeker AG, White E. Hepatitis B virus infection in dentists. N Engl J Med 1975;293:729-34.

Hepatitis B - Continued

- Smith JL, Maynard JE, Berquist KR, Doto IL, Webster HM, Sheller MJ. From the Center for Disease Control. Comparative risk of hepatitis B among physicians and dentists. J Infect Dis 1976; 133:705-6.
- Ahtone J, Goodman RA. Hepatitis B and dental personnel: transmission to patients and prevention issues. J Am Dent Assoc 1983;106:219-22.


Update: Influenza Activity - United States

Ten states reported widespread outbreaks of influenza-like illness, and 16 states reported regional outbreaks for the week ending February 2, 1985 (Figure 1). This was an increase in the number of states reporting widespread outbreaks from one state for the week ending January 19 and seven for the week ending January 26 (1).

The most recent states to report their first isolates of influenza type A(H3N2) virus for the season were Nebraska and Rhode Island. States reporting type A(H3N2) this season are Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Hawaii, Illiinois, Iowa, Kentucky, Louisiana, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, Tennessee, Texas, Utah, Washington, West Virginia, and Wisconsin.

During the last week of January, isolates of influenza type B virus from sporadic cases were reported for the first time this season from New York and South Dakota. Four other states (Hawaii, New Jersey, Ohio, and Texas) have reported type B viruses this season.

FIGURE 1. Influenza morbidity reported by state - United States, week ending February 2, 1985



^{*}Outbreaks involving areas with less than 50% of state's population.

[†]Outbreaks involving areas with more than 50% of state's population.

Influenza - Continued

Reported by V Pallidino, MD, S Litson, PhD, K Szabo, MD, Nassau County Medical Center, Long Island, New York; P Dennehy, MD, Providence Hospital, Providence, Rhode Island; State and Territorial Epidemiologists; State Laboratory Directors; Other collaborating laboratories; Statistical Svcs Br, Div of Surveillance and Epidemiologic Studies, Epidemiology Program Office, Influenza Br, Div of Viral Diseases, Center for Infectious Diseases, CDC.

Reference

1. CDC. Update: influenza activity-United States. MMWR 1985;34:62-3.

Notice to Readers

Ansamycin LM427

Since October 1983, CDC's Division of Tuberculosis Control, Center for Prevention Services, has supplied the experimental drug, ansamycin LM427, under a "compassionate" investigational new drug permit to physicians treating patients with serious mycobacterial disease unresponsive to conventional therapy. Beginning Monday, February 18, 1985, physicians requesting the drug for *new* patients should contact the CDC Drug Service at (404) 329-3670 during normal working hours. Ansamycin LM427 is not released at night or during weekends. The Division of Tuberculosis Control ([404] 329-2530) will continue to provide medical consultation on the treatment of mycobacterial diseases.

Director, Centers for Disease Control James O. Mason, M.D., Dr.P.H. Director, Epidemiology Program Office Carl W. Tyler, Jr., M.D. Editor Michael B. Gregg, M.D. Assistant Editor Karen L. Foster, M.A.

©U.S. Government Printing Office: 1985-746-149/10037 Region IV

DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Centers for Disease Control Atlanta GA 30333

Official Business Penalty for Private Use \$300



Postage and Fees Paid U.S. Dept. of H.H.S. HHS 396

